Navigation Links
Orapred ODT Tastes Good

Survey Shows 89% of Patients Prefer Orapred ODT Over Liquid

ALPHARETTA, Ga., March 29, 2007 /PRNewswire/ -- Alliant Pharmaceuticals announced today survey results showing that children prefer Orapred ODT(TM) (Prednisolone sodium phosphate orally disintegrating tablets) over liquid steroids.(1)

The results of the patient feedback survey involving more than 900 children (n=973), showed that 89% (n=870) of the children preferred Orapred ODT over liquid versions. The results also showed that 83% (n=809) of the respondents liked the taste of Orapred ODT, and 97% (n=942) said Orapred ODT was easy to take. In addition, 96% (n=937) of the patients reported that they were able to take all of their medication as prescribed.

Orapred ODT is the first orally disintegrating tablet form of prednisolone available in the United States. Orapred ODT is prescribed primarily for acute exacerbations of asthma in children. It is also used to control severe, persistent asthma and to reduce inflammation seen in numerous medical conditions including arthritis and cancer. The indication and important safety information for Orapred ODT is listed below.

"Orapred ODT's exclusive taste-masking technology helps disguise prednisolone's typically bitter taste," said Mark Pugh, President of Alliant Pharmaceuticals. "We are pleased to see that, based on these results; patients appreciate both the taste and convenience that Orapred ODT has to offer."

Orapred ODT utilizes a proprietary orally disintegrating tablet technology to provide a taste-masked, non refrigerated and convenient formulation of prednisolone.

Alliant Pharmaceuticals sponsored the survey that was initiated in September, 2006 and ran until December 2006. Patients were included in the multi-center survey if they required steroid burst therapy for asthma exacerbation and were required to have taken a liquid steroid in the past. Physicians were instr ucted to prescribe Orapred ODT according to NHLBI dosing guidelines of 1-2 mg per kg in single or divided doses. Patients were asked to respond to questions regarding taste, ease of use, preference over liquid steroid, and ability to take all medication as prescribed.

Important Safety Information

Orapred ODT(TM) (Prednisolone sodium phosphate orally disintegrating tablets) is a prescription drug product indicated for the control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with asthma or asthma caused by respiratory disorders. Orapred is contraindicated in patients with systemic fungal infections. Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered; however, the response to such vaccines cannot be predicted. Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison's disease. Orapred may cause mood swings. Adverse effects of Orapred include the following: endocrine (including development of cushingoid state, increased requirements for insulin or oral hypoglycemic agents in diabetic patients, manifestations of latent diabetes mellitus); fluid and electrolyte disturbances (including fluid retention, hypertension); gastrointestinal (including peptic ulcer with possible perforation and hemorrhage); increased appetite; and weight gain.

For additional safety information, please see full prescribing information available online at: http://www.orapredodt.com

Reference: 1. Patient Feedback Survey. Data on file as of 03/23/07. Alliant Pharmaceuticals, Inc.

About Alliant Pharmaceuticals, Inc.

Alliant Pharmaceuticals, Inc. is a Specialty Pharmaceutical company formed to develop and market a portfolio of innovative pharmaceutical products to pediatricians and pediatric specialty physicians. Alliant Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. Additional information about Alliant Pharmaceuticals in available online at: http://www.alliantpharma.com.

Media Contact: Sharon Kraun

Cohn, Overstreet & Parrish

404.961.2242 skraun@co-p.com

CONTACT: Sharon Kraun of Cohn, Overstreet & Parrish, +1-404-961-2242,, for Alliant Pharmaceuticals, Inc. skraun@co-p.com

Web site: http://www.alliantpharma.com/http://www.orapredodt.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):